Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 932 results for "novartis"

dna impact: Tata Memorial to repay cancer patients
DNA

dna impact: Tata Memorial to repay cancer patients

Tata Memorial Hospital has decided to reimburse cancer patients who were overcharged for a Novartis-branded oncology medicine over the last nine months. The hospital admitted to overcharging at its two pharmacies (one each in the main building and the Homi ... DNA, 9 hours ago

226 images for novartis

Times of India, 3 days ago
Boston Globe, 43 minutes ago
Pharmafocus, 1 day ago
EuroInvestor, 2 days ago
Boston Globe, 43 minutes ago
Irish Times, 4 days ago
Irish Independent, 3 days ago
FOXNews.com, 4 days ago
Investing.com, 5 days ago
Financial Express, 4 days ago
EuroInvestor

Europe Ad Comm gives thumbs up to Novartis psoriasis drug

News Editor The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting regulatory approval for Novartis' (NYSE:NVS) secukinumab for the first-line systemic treatment of adult patients ...
 Seeking Alpha1 day ago Novartis' Psoriasis Drug Secukinumab Gets Recommendation From CHMP  RTTNews.com2 days ago Novartis Cosentyx wins positive opinion from EMA's CHMP21-11-2014  Pharma Letter1 day ago EMA committee backs approval of Novartis' psoriasis therapy Cosentyx  FirstWord Pharma1 day ago
[x]  

Novartis calls for new approach to manage type 2 diabetes

IN OBSERVANCE of World Diabetes Day, Novartis Healthcare Philippines called for a new approach to the management of type 2 diabetes after a global survey revealed major disconnects in communication, disease awareness, and expectations between ...
 Philippine Daily Inquirer1 day ago
Reuters

Novartis (NVS) Receives CHMP's Approval For Psoriasis Drug

Novartis psoriasis treatment Cosentyx has received positive feedback from CHMP, the European Advisory Committee. If approved, the drug is likely to eat up sales of Amgen's Enbrel Page 1 of 2 Click Ticker to See live coverage Novartis AG ...
 Bidness Etc1 day ago Novartis' Enbrel beater bounds toward psoriasis approval ahead of the crowd  FierceBiotech1 day ago Novartis : Psoriasis Treatment Recommended for Approval by CHMP  4 Traders2 days ago Novartis Psoriasis Treatment Recommended for Approval by...  ADVFN India2 days ago
[x]  
Bidness Etc

Novartis AG Drug Gets Positive Recommendation; ChemoCentryx (CCXI) Stock Up on Orphan Drug Status

Here are the pharmaceutical stocks to keep an eye on today Page 1 of 2 Click Ticker to See live coverage The healthcare sector underperformed the broader tape second day in a row. The S&P 500 INDEX ( INDEXCBOE:SPX ) recovered from the ...
 Bidness Etc1 day ago ChemoCentryx's (CCXI) CCX168 Receives Orphan Drug Status  Bidness Etc1 day ago
Livemint.com

Novartis sees wearable technology as integral to healthcare

LONDON — Talent spotters from Novartis AG, charged with bringing new ideas into the organisation, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology. It's not that the world's biggest drugmaker by ...
 Japan Today2 days ago Novartis seeks tech partners for brave new beyond-the-pill world  FiercePharma3 days ago World's top drug maker Novartis takes aim at tech  Livemint.com4 days ago INTERVIEW-World's top drugmaker Novartis takes aim at tech  CNBC5 days ago
[x]  
Medical Design Online

Novartis, QIAGEN Sign Deal To Develop Companion Diagnostics

By Jof Enriquez QIAGEN, a provider of sample and assay technologies, recently signed an agreement with Swiss pharmaceutical firm Novartis to develop and commercialize companion diagnostics for Novartis existing and future portfolio of drugs.
 Medical Design Online2 days ago QIAGEN collaborates with Novartis to develop new companion diagnostics  Individual.com3 days ago Qiagen Enters Collaboration Agreement with Novartis  Individual.com6 days ago NOVARTIS : Qiagen Enters Collaboration Agreement with Novartis  4 Traders5 days ago

Positive data for Novartis psoriatic arthritis treatment drug

Recent results from Novartis show positive safety and efficacy data for a pair of phase III clinical trials on its drug secukinumab (AIN457) in the treatment of psoriatic arthritis. Data from the Future 1 and Future 2 studies showed that the drug ...
 Pharma Field3 days ago Novartis Drug Posts Positive Data  Austin American Statesman1 week ago Novartis reports positive results in spinal inflammation condition  Reuters1 month ago Novartis reports positive trials for arthritis drug secukinumab  Economic Times1 month ago

Novartis AG (NVS) Showing Bullish Technicals With Support At $94.83

Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) presents a trading opportunity that offers a 2.89% return in just 148 days. A covered call on Novartis AG at the $95.00 level expiring on Apr. '15 offers an assigned return rate ...
 Individual.com2 days ago Novartis AG (NVS) Trading Near $94.56 Resistance Level  Individual.com5 days ago Novartis AG (NVS) Trading Near $95.10 Resistance Level  Individual.com4 days ago
Pharma Letter

Novartis : to present first IL-17A Phase III data for AIN457 secukinumab in psoriatic arthritis and ankylosing spondylitis at ACR 2014

By a News Reporter-Staff News Editor at Pharma Business Week -- Novartis announced that data from two pivotal Phase III studies (FUTURE 1 and FUTURE 2) in psoriatic arthritis (PsA) patients and two pivotal Phase III studies (MEASURE 1 and MEASURE 2) ...
 4 Traders3 days ago Novartis announces phase III results of secukinumab showing rapid and significant efficacy in psoriatic arthritis patients  PharmaBiz5 days ago Novartis presents results from four pivotal Phase III studies for investigational drug secukinumab (AIN457) in psoriatic arthritis and ankylosing spondylitis at ACR 2014  Individual.com5 days ago Novartis presents positive results from phase III studies of AIN457 in ankylosing spondylitis at ACR Congress  PharmaBiz5 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less